Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | ABL1 | P00519 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.37 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2977375 | 0.91 | KDR (0.41) | HTR3ATP53MAPTABL1POLB | |
| SCHEMBL2977161 | 0.90 | HTR3A (0.54) | HTR3ATP53MAPTABL1POLB | |
| SCHEMBL13202767 | 0.85 | ALDH1A1 (0.44) | TP53MAPTPOLBLMNANAMPT | |
| SCHEMBL2962572 | 0.84 | ABL1 (0.46) | HTR3ATP53MAPTABL1POLB | |
| SCHEMBL2976622 | 0.82 | TP53 (0.47) | TP53MAPTLMNA | |
| SCHEMBL5352204 | 0.82 | TP53 (0.36) | TP53MAPTABL1POLBLMNA | |
| SCHEMBL2963756 | 0.82 | MAPT (0.47) | TP53MAPTPOLBRXFP1LMNA | |
| SCHEMBL2978633 | 0.79 | TP53 (0.44) | TP53MAPTSMN1; SMN2 | |
| SCHEMBL2977602 | 0.77 | S1PR1 (0.47) | TP53MAPTLMNASMN1; SMN2 | |
| SCHEMBL2971550 | 0.73 | MAPT (0.44) | TP53MAPTPOLBLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853573-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | Rigel Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | claimed |
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | claimed |
| WO-2006091858-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2006-08-31 | — | — | WO | claimed |
| US-7776847-B2 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1853573-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | Rigel Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | disclosed |
| WO-2006091858-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | HAVCR2, ZC3HAV1, MAVS | HTR3A 4430/4885TP53 561/4885MAPT 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.